Evidence map›Paper›PMID 35753058›Full record

ReviewEuropean journal of heart failure2022

Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?

Magdy Abdelhamid, Giuseppe Rosano, Marco Metra, Stamatis Adamopoulos, Michael Böhm, Ovidiu Chioncel, Gerasimos Filippatos, Ewa A Jankowska, Yury Lopatin, Lars Lund and 13 more

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. 2024 update in heart failure.ESC heart failure · 2025
    Review
  6. Article
  7. Ventricular arrhythmias in acute heart failure: a clinical consensus statement of the Association for Acute CardioVascular Care, the European Heart Rhythm Association, and the Heart Failure Association of the European Society of Cardiology.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 20 institutions in 16 countries.

Magdy AbdelhamidFaculty of Medicine, Kasr Al Ainy, Cardiology Department, Cairo University, Cairo, Egypt.
Giuseppe RosanoSt George's Hospitals, NHS Trust, University of London, London, UK.
Marco MetraInstitute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Stamatis AdamopoulosHeart Failure - Transplant - Mechanical Circulatory Support Unit, Onassis Cardiac Surgery Center, Athens, Greece.
Michael BöhmUniversitatsklinikum des Saarlandes, Klinik fur Innere Medizin III, Saarland University, Kardiologie, Angiologie und Internistische Intensivmedizin, Homburg/Saar, Germany.
Ovidiu ChioncelEmergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', University of Medicine Carol Davila, Bucharest, Romania.
Gerasimos FilippatosNational and Kapodistrian University of Athens, School of Medicine, University Hospital Attikon, Athens, Greece.
Ewa A JankowskaInstitute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Yury LopatinVolgograd State Medical University, Regional Cardiology Centre, Volgograd, Russian Federation.
Lars LundDepartment of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Davor MilicicUniversity of Zagreb School of Medicine, Zagreb, Croatia.
Brenda MouraArmed Forces Hospital, Porto, & Faculty of Medicine, University of Porto, Porto, Portugal.
Tuvia Ben GalDepartment of Cardiology, Rabin Medical Center, Petah Tikva, Israel, & Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Arsen RisticDepartment of Cardiology, University Clinical Center of Serbia, Belgrade University School of Medicine, Belgrade, Serbia.
Amina RakishevaScientific Research Institute of Cardiology and Internal Medicine, Almaty, Kazakhstan.
Gianluigi SavareseDepartment of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Wilfried MullensCardiovascular Physiology, Hasselt University, Belgium, & Heart Failure and Cardiac Rehabilitation Specialist, Ziekenhuis Oost-Limburg, Genk, Belgium.
Massimo PiepoliCardiac Unit, Guglielmo da Saliceto Hospital, University of Parma, Piacenza, Italy.
Antoni Bayes-GenisHeart Institute, Hospital Universitari Germans Trias i Pujol, Badalona & CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.
Thomas ThumInstitute of Molecular and Therapeutic Strategies, Hannover & Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany.
Stefan D AnkerDepartment of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charite Universitatsmedizin, Berlin, Germany.
Petar SeferovicDepartment Faculty of Medicine, University of Belgrade, Belgrade & Serbian Academy of Sciences and Arts, Belgrade, Serbia.
Andrew J S CoatsUniversity of Warwick, Coventry, UK.
Karolinska University Hospital · SEUniversity of Belgrade · RSAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITCairo University · EGCarol Davila University of Medicine and Pharmacy · ROFraunhofer Institute for Toxicology and Experimental Medicine · DEGerman Centre for Cardiovascular Research · DEGuglielmo da Saliceto Hospital · ITHospital Universitari Germans Trias i Pujol · ESKazakh Institute of Oncology and Radiology · KZNational and Kapodistrian University of Athens · GROnassis Cardiac Surgery Center · GRSt George’s University Hospitals NHS Foundation Trust · GBTel Aviv University · ILUniversidade do Porto · PTUniversitätsklinikum des Saarlandes · DEUniversity of Warwick · GBUniversity of Zagreb · HRVolgograd State Medical University · RUWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sudden death is a devastating complication of heart failure (HF). Current guidelines recommend an implantable cardioverter-defibrillator (ICD) for prevention of sudden death in patients with HF and reduced ejection fraction (HFrEF) specifically those with a left ventricular ejection fraction ≤35% after at least 3 months of optimized HF treatment. The benefit of ICD in patients with symptomatic HFrEF caused by coronary artery disease has been well documented; however, the evidence for a benefit of prophylactic ICD implantation in patients with HFrEF of non-ischaemic aetiology is less strong. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers (BB), and mineralocorticoid receptor antagonists (MRA) block the deleterious actions of angiotensin II, norepinephrine, and aldosterone, respectively. Neprilysin inhibition potentiates the actions of endogenous natriuretic peptides that mitigate adverse ventricular remodelling. BB, MRA, angiotensin receptor-neprilysin inhibitor (ARNI) have a favourable effect on reduction of sudden cardiac death in HFrEF. Recent data suggest a beneficial effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in reducing serious ventricular arrhythmias and sudden cardiac death in patients with HFrEF. So, in the current era of new drugs for HFrEF and with the optimal use of disease-modifying therapies (BB, MRA, ARNI and SGLT2i), we might need to reconsider the need and timing for use of ICD as primary prevention of sudden death, especially in HF of non-ischaemic aetiology.

Indexed as

Defibrillators, ImplantableHeart FailureAdrenergic beta-AntagonistsAldosteroneAngiotensin-Converting Enzyme InhibitorsAngiotensin IIAngiotensin Receptor AntagonistsDeath, Sudden, CardiacHumansMineralocorticoid Receptor AntagonistsNeprilysinNorepinephrinePrimary PreventionReceptors, AngiotensinSodium-Glucose Transporter 2 InhibitorsStroke VolumeAdrenergic beta-AntagonistsAldosteroneAngiotensin-Converting Enzyme InhibitorsAngiotensin IIAngiotensin Receptor AntagonistsMineralocorticoid Receptor AntagonistsNeprilysinNorepinephrineReceptors, AngiotensinSodium-Glucose Transporter 2 InhibitorsHeart failure with reduced ejection fractionImplantable cardioverter-defibrillatorSudden death

Identifiers

PMID35753058
OpenAlexW4283515856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.